MTND6P14

Across TCGA pan-cancer cohorts, MTND6P14 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated MTND6P14 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MTND6P14 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND6P14 expression acts as an unfavorable survival marker.

STAD, SKCM, and KICH are the cancer types where MTND6P14 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	III,IV	0.427	0.666	.003	78	view →
SKCM	DFS	Tertile	All	0.174	0.730	<.001	57	view →
KICH	DFS	Tertile	All	0.102	0.848	.004	39	view →
KIRC	DFS	Tertile	II,III,IV	0.248	0.661	.019	36	view →
DLBC	OS	Tertile	III,IV	0.175	0.874	.025	36	view →
KIRP	OS	Tertile	All	0.189	0.709	.002	33	view →
BLCA	DFS	Tertile	IV	0.124	0.469	.029	18	view →
UCEC	DFS	Tertile	III,IV	0.095	0.588	.012	18	view →
LIHC	OS	Tertile	All	0.156	0.774	.005	18	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MTND6P14–STAD (OS)

Open the STAD breakdown →